Demographics and disease manifestations of patients with granulomatosis with polyangiitis (GPA) with and without cardiac involvement.
| Demographics | GPA with Cardiac Involvement | GPA without Cardiac Involvement | p |
|---|---|---|---|
| Total, n | 17 | 500 | |
| Female, n (%) | 7 (41) | 262 (52) | 0.36 |
| Mean age at diagnosis, yrs (± SD) | 43.7 (16.5) | 45.9 (20.3) | 0.70 |
| Race, n (%) | 0.24 | ||
| White | 17 (100) | 442 (88) | |
| Nonwhite* | 0 | 58 (12) | |
| Time from symptom onset to diagnosis, mos (± SD) | 21 (28) | 14 (36) | 0.48 |
| Duration of followup, mos (± SD) | 97 (67) | 106 (71) | 0.68 |
| ANCA-positive, n (%)** | 16 (94) | 407 (81) | 0.33 |
| Anti-PR3–positive, n (%)# | 11 (65) | 338 (68) | 0.68 |
| Any history of flare† | 9 (53) | 325 (65) | 0.31 |
| Disease manifestations | |||
| Constitutional | 14 (82) | 400 (80) | 1.0 |
| Musculoskeletal | 10 (59) | 334 (67) | 0.49 |
| Skin | 8 (47) | 158 (32) | 0.12 |
| Mucus membranes | 1 (6) | 57 (11) | 1.0 |
| Eyes | 1 (6) | 163 (33) | 0.03 |
| Ear, nose, and throat | 13 (76) | 431 (86) | 0.28 |
| Lung | 14 (82) | 351 (70) | 0.42 |
| Gastrointestinal | 0 | 7 (1) | 1.0 |
| Kidney involvement | 10 (69) | 275 (55) | 0.55 |
| Nervous system involvement | 4 (24) | 109 (22) | 0.76 |
↵* Asian/Black/African American/Unknown race/mixed race or American Indian/Native Alaskan.
↵** Antineutrophil cytoplasmic antibody (ANCA), including cytoplasmic ANCA or perinuclear ANCA.
↵# Antiproteinase 3 antibody.
↵† Any history of flare defined as disease activity after a period of remission, either prior to enrollment in the Vasculitis Clinical Research Consortium (VCRC) or during subsequent VCRC followup.